<DOC>
	<DOCNO>NCT01934504</DOCNO>
	<brief_summary>The goal study find biological marker ( certain protein cellular marker find blood test ) inform doctor patient diagnose ANCA-associated vasculitis ( AAV ) likely able stop medication suppress immune system remain remission .</brief_summary>
	<brief_title>Defining Immune Tolerance ANCA-associated Vasculitis ( AAV )</brief_title>
	<detailed_description>Anti-neutrophil cytoplasmic antibody ( ANCA ) -associated vasculitides ( AAV ) small vessel vasculitides typically follow chronic course associate serious illness death.Three clinical condition recognize : microscopic polyangiitis ( MPA ) ; granulomatosis polyangiitis ( Wegener 's , GPA ) ; eosinophilic granulomatosis polyangiitis ( EPA , formerly Churg Strauss Syndrome ) . Though condition different clinical feature , overlap immunological characteristic . The precise cause AAV understood , clear genetic association , context predisposing environmental factor , infection , may lead development disease . There diagnostic criterion AAV , validate classification criterion disease definition . There need find biological marker define immunological tolerance immunotherapy medicine may correctly change safely withdrawn people .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<criteria>Tolerant AAV participant : Age 18 year old Diagnosis granulomatosis polyangiitis ( Wegener 's , GPA ) microscopic polyangiitis ( MPA ) accord definition Chapel Hill Consensus Conference ( CHCC ) History myeloperoxidase ( MPO ) ANCA positive disease flare In clinical remission Birmingham Vasculitis Activity Score Wegener 's Granulomatosis ( BVAS/WG ) = 0 immunosuppression ≥ 2 year Negative MPOANCA proteinase 3 ( PR3 ) ANCA ELISA screen For woman childbearing potential , negative urine serum pregnancy test time screen Ability sign understand inform consent Willingness comply study procedure . NonTolerant AAV participant : Age 18 year old Diagnosis granulomatosis polyangiitis ( Wegener 's ) , GPA microscopic polyangiitis ( MPA ) accord definition CHCC History MPOANCA positive disease flare Within past 5 year , must disease exacerbation , define increase BVAS/WG score reinstitution immunosuppressive therapy therapy reduce completely discontinue In clinical remission BVAS/WG = 0 minimal maintenance therapy ≥3 month prior screen visit . Minimal maintenance therapy define : Lowdose glucocorticoid ( ≤10 mg prednisone prednisolone daily ) and/or : Azathioprine ≤ 150mg daily Mycophenolate mofetil ( MMF ) ≤ 1 gram daily mycophenolate sodium ≤ 720 mg daily . Positive MPOANCA ELISA least 2 occasion within last 52 week , recent result within 8 week visit 1 For woman childbearing potential , negative urine serum pregnancy test time screen Ability sign understand inform consent Willingness comply study procedure . Healthy Controls : Healthy participant age ≥18 year For woman childbearing potential , negative urine serum pregnancy test time screen Ability sign understand inform consent Willingness comply study procedure . Tolerant AAV Participants : Use systemic intravenous ( IV ) oral glucocorticoid ˃ 1 month nonvasculitis indication within 8 week screen visit Any prior treatment rituximab Presence know chronic viral infection autoimmune disease History malignancy , exclude nonmelanomatous skin cancer cervical cancer carcinoma situ within 5 year screen visit . NonTolerant AAV participant : Use IV pulse glucocorticoid ( methylprednisolone ) cyclophosphamide within year prior screen visit Use IV oral glucocorticoid &gt; 1 month non vasculitis indication within 8 week screen visit Any prior treatment rituximab Maintenance therapy methotrexate within 3 month screen visit Presence know chronic viral infection autoimmune disease History malignancy , exclude nonmelanoma skin cancer cervical cancer carcinoma situ within 5 year screen visit . Healthy Controls : Use IV oral glucocorticoid &gt; 1 month nonvasculitis indication within 8 week screen visit Presence know chronic viral infection autoimmune disease History malignancy , exclude nonmelanoma skin cancer cervical cancer carcinoma situ within 5 year screen visit . AAV Participants Discontinuing Immunosuppression : Any prior treatment rituximab Maintenance therapy methotrexate within 3 month screen visit Presence know chronic viral infection autoimmune disease History malignancy , exclude nonmelanoma skin cancer cervical cancer carcinoma situ , within 5 year screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>clinical tolerance</keyword>
	<keyword>biomarker ( ) identification</keyword>
</DOC>